Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$620,000 |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$424M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$30,000 |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Nichols Weston | May 20, 2025 | Buy | 1,200,000 | $1.2 | $1.4M |
| Nichols Weston | May 19, 2025 | Buy | 1,388,794 | $1.2 | $1.7M |
| Nichols Weston | Dec 26, 2024 | Buy | 7,500,000 | $4 | $30M |
| Nichols Weston | Dec 13, 2024 | Buy | 100,000 | $2.9014 | $290,000 |
| Nichols Weston | Dec 12, 2024 | Buy | 31,800 | $3.0072 | $96,000 |
| Nichols Weston | Nov 15, 2024 | Buy | 947 | $4.3442 | $4,100 |
| Klencke Barbara | Sep 23, 2024 | Buy | 5,000 | $5.29 | $26,000 |
| Klencke Barbara | Aug 26, 2024 | Buy | 5,000 | $5.53 | $28,000 |
| ZDRAVESKI ZORAN | Aug 23, 2024 | Sell | 164,686 | $5.7814 | $950,000 |
| BAKER JULIAN | Apr 19, 2024 | Buy | 8,851,451 | $7.1299 | $63M |
| Nichols Weston | Apr 19, 2024 | Buy | 5,000,000 | $7.1299 | $36M |
| BAKER JULIAN | Apr 19, 2024 | Buy | 825,968 | $7.1299 | $5.9M |
| BARBERICH TIMOTHY J | Dec 19, 2023 | Buy | 317 | $4.9685 | $1,600 |
| BARBERICH TIMOTHY J | Dec 18, 2023 | Buy | 28,830 | $4.8866 | $140,000 |
| Klencke Barbara | Dec 14, 2023 | Buy | 5,000 | $5.08 | $25,000 |
| BARBERICH TIMOTHY J | Jun 2, 2023 | Buy | 37,880 | $2.6284 | $100,000 |
What's the latest insider transaction for Tscan Therapeutics?
The most recent insider transaction for Tscan Therapeutics was conducted by Nichols Weston, who sold 1,200,000 shares on May 20, 2025 at a price of $1.20 per share.
Which insider bought the most TCRX stock over the last two years?
Nichols Weston has bought the most TCRX stock in the last 2 years, with a total value of $69M.
Which insider has sold the most TCRX stock over the last two years?
ZDRAVESKI ZORAN has sold the most TCRX stock in the last 2 years, with a total value of $950,000.
What is the total value of insider transactions for Tscan Therapeutics (TCRX) in the last 2 years?
According to our estimates, the total value of insider transactions for Tscan Therapeutics in the last 2 years is positive, amounting to $138M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Tscan Therapeutics' market confidence?
Over the last 2 years, insider transactions for Tscan Therapeutics have predominantly involved purchasing shares, indicating a strong confidence among insiders in the company's future prospects. This trend of more purchases than sales could be a positive signal to potential investors about the insiders' view on the company's valuation and growth potential.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
